Post by Dr. David Langenberger

A notable development for the NGS industry: The Regional Court of Munich I has ruled that Illumina infringed patent rights controlled by Element Biosciences related to an imaging method used in DNA sequencing. According to Element’s announcement, the ruling goes beyond damages and accounting obligations, including an injunction against the supply of affected systems and consumables in Germany, as well as a recall order for certain products placed on the market since March 2023. Notably, the judgment explicitly references the MiSeq and MiSeqDx platforms and may extend to other systems that use the same imaging approach described by the court. If upheld, this could have significant implications for competition, product availability, and strategic positioning within the sequencing market. It also highlights how intellectual property continues to play a central role in shaping innovation and market dynamics in genomics. That said, this is a first-instance decision, and Illumina retains the right to appeal. The legal process is far from over. The next question will be whether this ruling leads to meaningful operational impact for laboratories and customers, or whether its long-term significance will primarily be felt through ongoing litigation and licensing discussions. #NGS #Genomics #Sequencing #LifeSciences #Biotech #Diagnostics #IntellectualProperty #PatentLitigation